뉴스

Ebola's Hidden Link To Gold Mining: Why Scientists Are Raising Alarm In Congo

Congo is home to one of the world's largest rainforest systems (File)

Russian Satellites Are Jamming GPS Signals Across Europe, Warn Scientists

Experts claimed that these incidents reflect a growing trend of electronic warfare (Representational)

How US immigration policy change may 'trouble' Apple, Google, OpenAI & other tech giants

A significant shift is underway in the AI race, with top Chinese scientists returning home from the US. Tightening American immigration policies and China's substantial investments in research and incentives are luring elite talent back. This exodus brings valuable AI expertise, including the pursuit of Artificial General Intelligence, to Chinese tech giants, potentially reshaping the global AI landscape.

A delayed monsoon, an emerging El Nino and the long shadow of India’s Great Famine

Nearly 150 years ago, a prolonged monsoon failure triggered one of India’s worst famines which claimed at least 55 lakh lives. As scientists track changing ocean-atmosphere conditions, an uneasy question lingers: will the Super El Nino replay the script of the 1876-78 tragedy?

Blood test can predict lung cancer 5 years before diagnosis

Scientists found blood markers that can predict lung cancer more than five years in advance. This breakthrough could help detect the disease early in India, where most cases are found late. A 14-protein signature in blood identified individuals at higher risk. This finding may lead to earlier monitoring and preventive measures for lung cancer.

Kalam School Of Ideology: Why Annamalai Chose The Scientist As His Guiding Light

K Annamalai quits BJP, launches 'We The Leader' movement promoting Kalam-inspired ethics and nationalism.

AHER and TJU collaboration has fostered world-class research, says U.S. scientist

Chennai-based CIBA scientists develop soil-friendly fertilisers from fish waste

The products address the twin challenges of scientific fish waste disposal and the growing need for eco-friendly nutrient sources that enhance soil fertility and agricultural productivity

Below-normal monsoon for Andhra Pradesh, but short, heavy spells likely: IMD

The State is likely to see more thunderstorms, lightning and strong winds during the southwest monsoon, affecting the agricultural activities, says IMD senior scientist

KAHER to award honorary doctorate to U.S. scientist during convocation

As many as 1,810 degrees, certificates to be awarded on Friday

What's Delaying Monsoon? Scientists Point To Indian Ocean, El Nino

Centre has put itself on alert mode to deal with the possible impact of El Nino (Representational)

Melissa Casias' body discovered: From Los Alamos to NASA, the timeline behind America's missing scientists mystery

Melissa Casias, a nuclear lab worker, was found dead in Carson National Forest after disappearing on 26 June, 2025. Her case adds to a trend of mysterious deaths and disappearances among individuals connected to US nuclear and aerospace programs. Here we examine the timeline of these events.

Climate Change Will Make Super El Nino Especially Severe, Scientists Warn

WMO forecasts suggest a strong El Nino is possible.

Strong El Niño likely this year, climate change could intensify extreme weather: WMO

The World Meteorological Organization warns of an 80% chance of a strong El Niño developing this year, potentially amplifying extreme weather events due to climate change. This phenomenon, characterized by warmer Pacific waters, could lead to intensified heatwaves, droughts, and floods globally. Scientists fear this combination may make 2027 the hottest year on record.

Europe AI startup co-founder warns region cannot afford to rely on US for Superintelligence

Europe faces a critical need to develop its own superintelligence. Mistral AI's chief scientist warns against relying on American tech giants for future AI advancements. This push for independence is driven by geopolitical shifts. Mistral AI aims to provide European-hosted AI models. However, funding remains a significant challenge for the startup.

'De-extincting' the Moa: The audacious bid to bring back the giant bird

A Texas-based firm, Colossal Biosciences, claims a breakthrough in de-extinction, developing an artificial eggshell system to potentially resurrect the extinct moa. While scientists express skepticism due to a lack of peer-reviewed data, the project is driven by ecological restoration, cultural significance for Māori, and the development of biotechnology for living endangered species.

Nagaland yields a new-to-science cascade frog species

Recorded from Kiphire district, the frog has been named Amolops kamal to honour the mentor of one of the six scientists involved in the study

Scientists develop 'smart paint' that reflects 97% of sunlight and could reduce AC use during heatwaves

Molecule glue drugs shake up cancer care

One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.

CCMB scientists identify rare gene behind Indian girl’s red hair

From this, researchers have provided fresh insight into the country’s complex genetic landscape by uncovering the role of the MC1R gene (melanocortin 1 receptor), a key regulator of skin and hair pigmentation.